---
title: "Novo and Medicare’s Bridge program: what STAT reported and what wasn’t disclosed"
id: "stat-news-1-stat-novo-may-be-getting-a-better-deal-than-expected-with-medicare-s-bridge"
canonical_url: "https://medichelpline.com/clinical-feed/stat-news-1-stat-novo-may-be-getting-a-better-deal-than-expected-with-medicare-s-bridge"
content_type: "clinical_feed_article"
specialty: "Pharmacology"
source_name: "STAT News"
source_url: "https://www.statnews.com/2026/09/22/biotech-news-novo-may-be-getting-a-better-deal-than-expected-with-medicare-bridge/?utm_campaign=rss"
published_at: "2026-09-22T14:23:00.000Z"
evidence_level: "Verified Feed"
license: "CC-BY-NC-4.0 / Informational Use"
---
# Novo and Medicare’s Bridge program: what STAT reported and what wasn’t disclosed
## Provenance & Clinical Metadata
- **Canonical URL:** https://medichelpline.com/clinical-feed/stat-news-1-stat-novo-may-be-getting-a-better-deal-than-expected-with-medicare-s-bridge
- **Specialty:** [Pharmacology](https://medichelpline.com/clinical-feed/pharmacology.md)
- **Primary Source:** STAT News
- **Source URL:** [Original Journal Publication](https://www.statnews.com/2026/09/22/biotech-news-novo-may-be-getting-a-better-deal-than-expected-with-medicare-bridge/?utm_campaign=rss)
- **Published At:** 2026-09-22T14:23:00.000Z
- **Evidence Rating:** Verified Feed
## Executive GIST (TL;DR)
- STAT reported a headline suggesting **Novo** may be receiving more favorable terms than expected from **Medicare’s Bridge program**, but the full article is behind the STAT+ paywall and substantive details were not provided in the free excerpt. - The public portion of the article highlights several biotech trial updates: Roche reported positive Phase 2 results for **enicepatide** in patients with type 2 diabetes and obesity; Roche plans additional pivotal work including a trial focused on blood sugar control and cardiovascular outcomes. - **Celldex Therapeutics** announced that an experimental therapy for chronic hives met the primary goals in two Phase 3 trials, as noted in STAT’s roundup. - **Ionis Pharmaceuticals** reported positive Phase 3 topline results for an RNA-based therapy called **ulefnersen** in a rare form of ALS; the drug is licensed to **Otsuka**. - **Viking Therapeutics** said a Phase 2 maintenance study of its injectable obesity candidate VK2735, a **GLP-1–GIP agonist**, showed maintained efficacy when dosing moved from weekly to every-other-week or monthly schedules. - The publicly available excerpt includes a STAT+ paywall notice: the detailed reporting and analysis about Novo and the Medicare Bridge program are accessible only to subscribers; the excerpt does not report specific deal terms, financials, Medicare communications, or regulatory steps. - Where the excerpt omits specifics (deal structure, pricing implications, Medicare responses, Novo statements beyond the headline), those details were not reported in the available source and cannot be inferred. - The roundup situates the headline among broader biotech developments (trial readouts, company announcements), but the core claim about Novo and Medicare’s Bridge program remains unsupported by detailed, reportable facts in the free text. - Readers seeking the full investigative context, evidence, and any quoted sources must consult the STAT+ subscription article; the free excerpt directs readers to subscribe to read the rest.
## Clinical Analysis & Structured Key Points
[Skip to Main Content](https://www.statnews.com/2026/09/22/biotech-news-novo-may-be-getting-a-better-deal-than-expected-with-medicare-bridge/?utm_campaign=rss#wrapper) [ ![STAT](https://www.statnews.com/wp-content/themes/stat/images/stat-logo-white.svg) ![STAT](https://www.statnews.com/wp-content/themes/stat/images/stat-logo.svg) ](https://www.statnews.com/) * [Manage alerts for this article](https://www.statnews.com/my-account/edit/#emails) * [Save this story for later](https://www.statnews.com/my-account/saved/) * [Share this article](https://www.statnews.com/2026/09/22/biotech-news-novo-may-be-getting-a-better-deal-than-expected-with-medicare-bridge/?utm_campaign=rss) [Cancer](https://www.statnews.com/topic/cancer/) [FDA](https://www.statnews.com/topic/fda/) [research](https://www.statnews.com/topic/research/) * [Newsletters](https://www.statnews.com/signup/) * [Log In](https://www.statnews.com/login/) * [My Account](https://www.statnews.com/my-account/) * [Subscribe Now](https://www.statnews.com/stat-plus/) My Account * [Settings Complete your personal information for a more tailored experience ](https://www.statnews.com/my-account/) * [Saved Stories](https://www.statnews.com/my-account/saved/) * [Billing](https://www.statnews.com/my-account/billing/) * [Log In](https://www.statnews.com/login/) [ ![STAT](https://www.statnews.com/wp-content/themes/stat/images/stat-logo.svg) Reporting from the frontiers of health and medicine ](https://www.statnews.com/) * [Newsletters](https://www.statnews.com/signup/) * [Log In](https://www.statnews.com/login/) * [My Account](https://www.statnews.com/my-account/) * [Subscribe Now](https://www.statnews.com/stat-plus/) * [Biotech](https://www.statnews.com/category/biotech/) * [Pharma](https://www.statnews.com/category/pharma/) * [Public Health](https://www.statnews.com/category/health/) * [Health Tech](https://www.statnews.com/category/health-tech/) * [Policy](https://www.statnews.com/category/politics/) * [Science](https://www.statnews.com/category/in-the-lab/) * [First Opinion](https://www.statnews.com/category/first-opinion/) * [STAT+](https://www.statnews.com/topic/stat-plus/) * [STAT Events](https://www.statnews.com/events/) [ ![STAT](https://www.statnews.com/wp-content/themes/stat/images/stat-logo.svg) ](https://www.statnews.com/) Search * [Log In](https://www.statnews.com/login/) * [Subscribe Now](https://www.statnews.com/stat-plus/) * [My Account](https://www.statnews.com/my-account/) My Account * [Settings](https://www.statnews.com/my-account/) * [Saved Stories](https://www.statnews.com/my-account/saved/) * [Billing History](https://www.statnews.com/my-account/billing/) [Home](https://www.statnews.com/) News * [Latest](https://www.statnews.com/latest/) * [Series & Investigations](https://www.statnews.com/stat-series-and-investigations-award-winning-journalism/) * Business * [Biotech](https://www.statnews.com/category/biotech/) * [Pharma](https://www.statnews.com/category/pharma/) * [Health Tech](https://www.statnews.com/category/health-tech/) * [Health Insurance](https://www.statnews.com/category/insurance/) * [Hospitals](https://www.statnews.com/category/hospitals/) * [Medical Devices](https://www.statnews.com/topic/medical-devices/) * Washington * [Policy](https://www.statnews.com/category/politics/) * [FDA](https://www.statnews.com/topic/fda/) * [NIH](https://www.statnews.com/topic/nih/) * Science * [CRISPR](https://www.statnews.com/topic/crispr/) * [Gene Therapy](https://www.statnews.com/topic/gene-therapy/) * [Neuroscience](https://www.statnews.com/topic/neuroscience/) * Public Health * [Addiction](https://www.statnews.com/topic/addiction/) * [Covid-19](https://www.statnews.com/topic/coronavirus/) * [Abortion](https://www.statnews.com/topic/abortion/) * [Health Disparities](https://www.statnews.com/topic/health-disparities/) * [Infectious Disease](https://www.statnews.com/topic/infectious-disease/) * [Mental Health](https://www.statnews.com/topic/mental-health/) * Disease * [Cancer](https://www.statnews.com/topic/cancer/) * [Cardiovascular Disease](https://www.statnews.com/topic/cardiovascular-disease/) * [Chronic Disease](https://www.statnews.com/topic/chronic-disease/) * [Diabetes](https://www.statnews.com/topic/diabetes/) * [Alzheimer's](https://www.statnews.com/topic/alzheimers/) * [Obesity](https://www.statnews.com/topic/obesity/) * Features * [Health Care Costs](https://www.statnews.com/health-insurance-costs-out-of-pocket-out-of-reach-series/) * [The Deadliest Drug](https://www.statnews.com/alcohol-epidemic-hiding-plain-sight-deadliest-drug-series/) * [Science, Shattered](https://www.statnews.com/american-science-shattered/) [Newsletters](https://www.statnews.com/signup/) [Opinion](https://www.statnews.com/category/first-opinion/) Columns * [Adam Feuerstein](https://www.statnews.com/category/adams-take/) * [Matthew Herper](https://www.statnews.com/category/matts-take/) * [Ed Silverman](https://www.statnews.com/category/pharmalot-view/) [Reports](https://reports.statnews.com/) [E-books](https://www.statnews.com/ebooks/) [Podcasts](https://www.statnews.com/podcasts/) [Tools & Trackers](https://www.statnews.com/trackers/) * [CRISPR Tracker](https://www.statnews.com/feature/crispr/tracker/) * [Breakthrough Device Tracker](https://www.statnews.com/feature/stat-plus/breakthrough-device-designation-fda-tracker/) * [Generative AI Tracker](https://www.statnews.com/feature/stat-plus/generative-ai-health-hospitals-tracker/) * [Obesity Drug Tracker](https://www.statnews.com/2023/09/12/new-weight-loss-drug-tracker-novo-nordisk-eli-lilly/) [Events](https://www.statnews.com/events/) * [Upcoming Events](https://www.statnews.com/events#upcoming-events) * [Summits](https://www.statnews.com/stat-summits/) [Community](https://www.statnews.com/community/) * [STAT Wunderkinds 2026](https://www.statnews.com/wunderkinds-nominate/) [Video](https://youtube.com/@Statnews) [Advertise](https://www.statnews.com/advertise/) * [STAT Brand Studio](https://sbs.statnews.com/) What's the word? Test your knowledge with our new weekday mini crossword [ Start solving ](https://www.statnews.com/stat-mini-crossword/) [STAT Plus](https://www.statnews.com/stat-plus/)Newsletter[The Readout](https://www.statnews.com/category/readout-newsletter/) # Novo may be getting a better deal than expected with Medicare’s Bridge program ## Viking’s obesity drug’s Phase 2 results, Lexeo expands beyond gene therapies, and more biotech news * [Manage alerts for this article](https://www.statnews.com/my-account/edit/#emails) * [Save this story for later](https://www.statnews.com/my-account/saved/) * [Share this article](https://www.statnews.com/2026/09/22/biotech-news-novo-may-be-getting-a-better-deal-than-expected-with-medicare-bridge/?utm_campaign=rss) ![Novo Nordisk's logo on a building](https://www.statnews.com/wp-content/uploads/2025/04/AdobeStock_1068642359_Editorial_Use_Only-645x645.jpeg) Adobe ![](https://www.statnews.com/wp-content/uploads/2022/12/elaine-chen-avatar-round-80x80.png) By [Elaine Chen](https://www.statnews.com/staff/elaine-chen/) Sept. 22, 2026 National Biotech Reporter ![](https://www.statnews.com/wp-content/uploads/2022/12/elaine-chen-avatar-round-80x80.png) [Elaine Chen](https://www.statnews.com/staff/elaine-chen/) 1. [](https://www.linkedin.com/in/elaineywchen/ "Linkedin") 2. [](https://x.com/elaineywchen "X") elaine.chen@statnews.com Elaine’s stories explore the boom in new obesity treatments, new drug payment models, the ways companies are affected by FDA changes, and the emerging psychedelics drug sector. She co-writes [The Readout newsletter](https://www.statnews.com/signup/readout/), and co-hosts STAT’s weekly biotech podcast, [The Readout Loud](https://www.statnews.com/category/readout-loud/). You can reach Elaine on Signal at elaineywchen.70. [Subscribe](https://www.statnews.com/stat-plus/) or [log in](https://www.statnews.com/login/) to STAT+ to unlock email alerts _Want to stay on top of the science and politics driving biotech today?[Sign up](https://www.statnews.com/signup/readout/) to get our biotech newsletter in your inbox._ Good morning. As an avid Pilates goer, I appreciated [this story.](https://www.wsj.com/lifestyle/fitness/gym-bros-pilates-solidcore-classes-b3b0e5d5) Advertisement ## The need-to-know this morning * Roche _[reported](https://www.roche.com/media/releases/med-cor-2026-09-22)_ a positive Phase 2 trial of enicepatide (previously known as CT-388) in patients with type 2 diabetes and obesity, with the drug helping patients lose weight and lower blood sugar. The company already has two Phase 3 weight loss studies ongoing and is planning on starting another pivotal trial next year looking at blood sugar control and cardiovascular outcomes. * **Celldex Therapeutics** said its experimental treatment for chronic hives [achieved the goals](https://ir.celldex.com/news-releases/news-release-details/celldex-announces-positive-results-phase-3-embarq-csu1-and) of two Phase 3 clinical trials. * **Ionis Pharma** said an experimental therapy for a rare form of ALS [prolonged survival and slowed the progression of the disease](https://ir.ionis.com/news-releases/news-release-details/ionis-announces-positive-topline-results-phase-3-fusion-study) in a Phase 3 clinical trial. The RNA-based drug, called ulefnersen, is licensed to the Japanese pharma company **Otsuka**. ## Viking drug shows potential for less frequent maintenance dosing Viking Therapeutics [said](https://ir.vikingtherapeutics.com/2026-09-22-Viking-Therapeutics-Announces-Positive-Topline-Results-from-Maintenance-Study-of-GLP-1-GIP-Agonist-VK2735-Demonstrating-the-Promise-of-Multiple-Maintenance-Dosing-Regimens) this morning that in a Phase 2 trial, its injectable obesity candidate, initially tested as a weekly treatment, still looked to be efficacious after transitioning to every-other-week or monthly dosing. [![STAT+](https://www.statnews.com/wp-content/themes/stat/images/stat-plus-logo.svg)](https://www.statnews.com/stat-plus/) To read the rest of this story subscribe to STAT+. [Subscribe](https://www.statnews.com/stat-plus/) [Log In](https://www.statnews.com/login/) [biotechnology](https://www.statnews.com/topic/biotechnology/), [drug development](https://www.statnews.com/topic/drug-development/), [Drug prices](https://www.statnews.com/topic/drug-prices/), [research](https://www.statnews.com/topic/research/) [Submit a correction request](https://www.statnews.com/contact/?how_can_we_help_=Editorial%20Correction%20Request)[Reprints](https://www.parsintl.com/publications/stat/) 1. ![](https://www.statnews.com/wp-content/uploads/2022/12/elaine-chen-avatar-round-80x80.png) [Elaine Chen](https://www.statnews.com/staff/elaine-chen/) 1. [](https://x.com/elaineywchen "X") 2. [](https://bsky.app/profile/elaineywchen.bsky.social "Bluesky") 3. 4. [](https://www.linkedin.com/in/elaineywchen/ "Linkedin") National Biotech Reporter 1. [](https://x.com/elaineywchen "X") 2. [](https://bsky.app/profile/elaineywchen.bsky.social "Bluesky") 3. 4. [](https://www.linkedin.com/in/elaineywchen/ "Linkedin") Elaine’s stories explore the boom in new obesity treatments, new drug payment models, the ways companies are affected by FDA changes, and the emerging psychedelics drug sector. She co-writes [The Readout newsletter](https://www.statnews.com/signup/readout/), and co-hosts STAT’s weekly biotech podcast, [The Readout Loud](https://www.statnews.com/category/readout-loud/). You can reach Elaine on Signal at elaineywchen.70. ![](https://www.statnews.com/wp-content/themes/stat/images/article-new/envelope-open.svg) ![](https://www.statnews.com/wp-content/uploads/2023/06/The-Readout-Logo-Black-640x99.png) ### Newsletter Your morning rundown of the science, politics, and money driving biotech today Please enter a valid email address. Sign Up Your data will be processed in accordance with our [Privacy Policy](https://www.statnews.com/privacy/) and [Terms of Service](https://www.statnews.com/terms-conditions/). You may opt out of receiving STAT communications at any time. Advertisement Most Popular 1. ![](https://www.statnews.com/wp-content/uploads/2026/09/AP6802385202387510-80x80.jpg) ![](https://www.statnews.com/wp-content/themes/stat/images/home/statplus.svg) [What a vote on Grail’s cancer detection test could mean for the company, patients, and regulators](https://www.statnews.com/2026/09/21/grail-galleri-fda-advisory-committee-meeting-documents/) 2. ![](https://www.statnews.com/wp-content/uploads/2026/09/AdobeStock_137807420-80x80.jpeg) ![](https://www.statnews.com/wp-content/themes/stat/images/home/statplus.svg) [Why an influential GOP health policy expert still backs the Medicaid cuts — and which policy target is next](https://www.statnews.com/2026/09/22/brian-blase-paragon-health-institute-gop-aca-medicaid-reforms/) 3. ![](https://www.statnews.com/wp-content/uploads/2026/09/GettyImages-2294340438-80x80.jpg) ![](https://www.statnews.com/wp-content/themes/stat/images/home/statplus.svg) [Members of Congress push back on plan to create a commission of political appointees to review NIH grants](https://www.statnews.com/2026/09/21/trump-plan-for-commission-to-review-nih-grants-push-back/) 4. ![](https://www.statnews.com/wp-content/uploads/2026/09/OHGV_0309-80x80.jpg) ![](https://www.statnews.com/wp-content/themes/stat/images/home/statplus.svg) [Ohio governor’s race is a battle over Covid, health costs, and trust in science](https://www.statnews.com/2026/09/22/ohio-governor-election-health-care-policy-acton-ramaswamy/) 5. ![](https://www.statnews.com/wp-content/uploads/2025/07/mike-doustdar-3-80x80.jpeg) ![](https://www.statnews.com/wp-content/themes/stat/images/home/statplus.svg) [With new strategy, Novo outlines plans for obesity, direct-to-consumer work](https://www.statnews.com/2026/09/21/novo-nordisk-capital-markets-day-obesity-strategy/) #### [ Reports ](https://reports.statnews.com/) [ ![](https://www.statnews.com/wp-content/uploads/2026/08/2026_CancerReport_ReportCover-328x424.jpg) Explore Cancer’s transformational moments: KRAS, CAR-T, immunotherapy, and more ](https://reports.statnews.com/products/cancer-transformational-moments-advances-in-kras-car-t-immunotherapy) Advertisement #### [Events](https://www.statnews.com/events/) [ ![](https://www.statnews.com/wp-content/uploads/2026/07/924_Samsung_VirtualEvent_Wordpress_FeaturedImage-80x80.jpg) Biosimilars: Have We Reached an Inflection Point? Virtual Sep 24 ](https://www.statnews.com/event/biosimilars-what-is-next-virtual-event-sept-2026/) [ ![](https://www.statnews.com/wp-content/uploads/2026/01/Flagship2026_Wordpress_CalendarImageRegGoLive-1-80x80.jpg) 2026 STAT Summit Boston, MA Oct 14 ](https://www.statnews.com/event/2026-stat-summit/) [ ![](https://www.statnews.com/wp-content/uploads/2026/07/2026_DD_OfficeHours_VirtualEvent_Wordpress_CalendarImage-80x80.jpg) Office Hours with Isabella Cueto and Lev Facher Virtual Jul 29 ](https://www.statnews.com/event/deadliest-drug-series-office-hours-ama-july-2026/) Most Read in [STAT+](https://www.statnews.com/stat-plus/) 1. ![](https://www.statnews.com/wp-content/uploads/2025/12/AdobeStock_288008063-80x80.jpeg) ![](https://www.statnews.com/wp-content/themes/stat/images/home/statplus.svg) [Vera kidney drug Trutakna shows strong final results in Phase 3 trial](https://www.statnews.com/2026/09/15/vera-kidney-drug-trutakna-shows-strong-phase-3-results-igan/) 2. ![](https://www.statnews.com/wp-content/uploads/2026/09/Eliza-treated-with-Gene-therapy-2016-80x80.jpg) ![](https://www.statnews.com/wp-content/themes/stat/images/home/statplus.svg) [FDA approves a new gene therapy for Sanfilippo syndrome, an ultra-rare disease](https://www.statnews.com/2026/09/17/sanfilippo-syndrome-treatment-ultragenyx-approval/) 3. ![](https://www.statnews.com/wp-content/uploads/2022/06/AdamsTake_Illustration_MollyFerguson_061322-80x80.jpg) ![](https://www.statnews.com/wp-content/themes/stat/images/home/statplus.svg) [A Sellas immunotherapy study, long delayed, will end in failure](https://www.statnews.com/2026/09/17/sellas-immunotherapy-study-acute-myeloid-leukemia/) 4. ![](https://www.statnews.com/wp-content/uploads/2025/12/AdobeStock_1649079417-80x80.jpeg) ![](https://www.statnews.com/wp-content/themes/stat/images/home/statplus.svg) [A biotech hedge fund births a new immunology company ](https://www.statnews.com/2026/09/17/biotech-hedge-fund-startup-north-immunology/) 5. ![](https://www.statnews.com/wp-content/uploads/2026/09/GettyImages-2292889136-80x80.jpg) ![](https://www.statnews.com/wp-content/themes/stat/images/home/statplus.svg) [Medicare to expand its pilot that pays for technology to manage chronic diseases](https://www.statnews.com/2026/09/15/medicare-access-chronic-care-management-tech-pilot-expanding/) #### Recommended ![](https://www.statnews.com/wp-content/plugins/stat-lazy-load/images/328x185-00000000.png) Politics Politics September 22, 2026 ### ![](https://www.statnews.com/wp-content/themes/stat/images/home/statplus.svg) [ STAT Plus: Ohio governor’s race is a battle over Covid, health costs, and trust in science ](https://www.statnews.com/2026/09/22/ohio-governor-election-health-care-policy-acton-ramaswamy/) By [Sarah Todd](https://www.statnews.com/staff/sarah-todd/) ![](https://www.statnews.com/wp-content/plugins/stat-lazy-load/images/328x185-00000000.png) Health Health September 21, 2026 ### ![](https://www.statnews.com/wp-content/themes/stat/images/home/statplus.svg) [ STAT Plus: What a vote on Grail’s cancer detection test could mean for the company, patients, and regulators ](https://www.statnews.com/2026/09/21/grail-galleri-fda-advisory-committee-meeting-documents/) By [Matthew Herper](https://www.statnews.com/staff/matthew-herper/) Advertisement ![](https://www.statnews.com/wp-content/plugins/stat-lazy-load/images/328x185-00000000.png) The Readout The Readout September 21, 2026 ### ![](https://www.statnews.com/wp-content/themes/stat/images/home/statplus.svg) [ STAT Plus: Lilly’s breast cancer combo wins approval ](https://www.statnews.com/2026/09/21/biotech-news-lilly-breast-cancer-combo-wins-approval/) By STAT Staff ![](https://www.statnews.com/wp-content/plugins/stat-lazy-load/images/328x185-00000000.png) Biotech Biotech September 21, 2026 ### ![](https://www.statnews.com/wp-content/themes/stat/images/home/statplus.svg) [ STAT Plus: Alkermes’ orexin agonist shows potential to treat ADHD in early-stage trial ](https://www.statnews.com/2026/09/21/alkermes-orexin-agonist-adhd-study/) By [Elaine Chen](https://www.statnews.com/staff/elaine-chen/) ![](https://www.statnews.com/wp-content/plugins/stat-lazy-load/images/328x185-00000000.png) Pharma Pharma September 20, 2026 ### ![](https://www.statnews.com/wp-content/themes/stat/images/home/statplus.svg) [ STAT Plus: Radiopharma companies merge after one receives surprise FDA rejection ](https://www.statnews.com/2026/09/20/radiopharma-companies-itm-telix-merger/) By [Allison DeAngelis](https://www.statnews.com/staff/allison-deangelis/) #### Subscriber Picks 1. ### ![](https://www.statnews.com/wp-content/themes/stat/images/home/statplus.svg) [ STAT Plus: A Sellas immunotherapy study, long delayed, will end in failure ](https://www.statnews.com/2026/09/17/sellas-immunotherapy-study-acute-myeloid-leukemia/) By [Adam Feuerstein](https://www.statnews.com/staff/adam-feuerstein/) 2. ### ![](https://www.statnews.com/wp-content/themes/stat/images/home/statplus.svg) [ STAT Plus: Medicare's AI prior authorization pilot was rushed and full of problems, new documents reveal ](https://www.statnews.com/2026/09/15/medicare-wiser-ai-prior-authorization-pilot-rushed-launch-delayed-care/) By [Br
## Related Clinical Research

- [Sanofi Pompe drug shortages, Jazz Pharma buys Actio, and Lilly’s Foundayo OKed in U.K.](https://medichelpline.com/clinical-feed/stat-news-4-stat-pharmalittle-we-re-reading-about-a-sanofi-drug-shortage-a-jazz-pharma-deal.md)
- [New ACC/AHA Guidance on Cardiovascular Care for Tactical Athletes](https://medichelpline.com/clinical-feed/stat-news-1-tactical-athletes-get-new-guidance-for-cardiovascular-fitness.md)
- [Waist circumference predicts mortality more than BMI in adults 65+: study findings](https://medichelpline.com/clinical-feed/medical-news-today-0-bmi-vs-waist-size-study-finds-belly-fat-matters-more-than-weight-for-death-risk.md)
- [Keto Diet Shows Superior Metabolic Benefits Over Mediterranean and Low-Fat Diets](https://medichelpline.com/clinical-feed/medical-news-today-1-keto-diet-may-have-metabolic-advantages-over-mediterranean-low-fat-diets.md)

## Navigation
- [← Back to Pharmacology Feed](https://medichelpline.com/clinical-feed/pharmacology.md)
- [← All Clinical Specialties](https://medichelpline.com/clinical-feed.md)
## Medical & Regulatory Disclaimer

> [!CAUTION]
> MedicHelpline content is structured for research, educational, and professional discovery purposes. It does not constitute individual medical advice, clinical diagnosis, or treatment recommendations.
> Always verify dosing, contraindications, and regulatory alerts against official product labeling and primary regulatory sources before clinical decision-making.